Biolife Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>BS</div>
BLFS -- USA Stock  

USD 33.70  0.11  0.33%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to sum up Biolife Solutions against current market trends. As we have suggested previously, Biolife Solutions is beginning its fall as retail investors shift to be more bearish due to the increased sector volatility. The returns on the market and returns on Biolife Solutions appear slightly correlated to each other for the last few months. Weak technical and fundamental indicators of the enterprise may also connote signs of long-running losses for Biolife retail investors. Biolife Solutions is scheduled to announce its earnings today. The next earnings report is expected on the 13th of May 2021.
Published over three weeks ago
View all stories for Biolife Solutions | View All Stories
Our latest technical analysis of Biolife Solutions (NASDAQ:BLFS)
The company's average rating is Buy from 7 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Biolife Solutions market sentiment investors' perception of the future value of Biolife. Let us look at a few aspects of Biolife technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Biolife Solutions. In general, we focus on analyzing Biolife Solutions stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biolife Solutions's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Biolife Solutions's intrinsic value. In addition to deriving basic predictive indicators for Biolife Solutions, we also check how macroeconomic factors affect Biolife Solutions price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Biolife Solutions' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Biolife Solutions in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Biolife Solutions. Your research has to be compared to or analyzed against Biolife Solutions' peers to derive any actionable benefits. When done correctly, Biolife Solutions' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Biolife Solutions.

How does Biolife Stands against Peers?

Analyzing Biolife Solutions competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Biolife Solutions across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Biolife Solutions Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Biolife Solutions, but it might be worth checking our own buy vs. sell analysis

What is driving Biolife Solutions Investor Appetite?

Biolife Solutions has a beta of -0.3815. Let's try to break down what Biolife's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biolife Solutions will likely underperform. The beta indicator helps investors understand whether Biolife Solutions moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Biolife deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity reported the previous year's revenue of 41.66 M. Net Income was 7.3 M with profit before overhead, payroll, taxes, and interest of 18.9 M.

Biolife Solutions has a good chance to finish above $39 in 2 months

Latest mean deviation is at 2.89. Biolife Solutions exhibits very low volatility with skewness of 0.21 and kurtosis of -0.13. However, we advise investors to further study Biolife Solutions technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biolife Solutions' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biolife Solutions' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Biolife Solutions Investment

While other companies in the medical instruments & supplies industry are either recovering or due for a correction, Biolife Solutions may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 22nd of March 2021, our research shows that Biolife Solutions is a rather very steady investment opportunity with a average chance of distress in the next two years. From a slightly different view, the entity currently appears to be fairly valued. However, our ongoing 30 days 'Buy-vs-Sell' recommendation on the enterprise is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Biolife Solutions. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com